Dr. Mayor on Neuroendocrine Carcinoma in Gynecologic Tumors

Paul Mayor, MD
Published: Wednesday, May 23, 2018



Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.

In a comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors, investigators identified mutations in various pathways. Mayor said that there were a significant number of p53 and Rb mutations, which are very common in neuroendocrine tumors from sites other than the gynecologic tract. This was expected.

There were a significant number of actionable mutations in the gynecologic subgroup, which Mayor said was unexpected. These actionable mutations were found in the mTOR, MEK, and homologous recombination repair pathways. About 60% of the patients had a mutation that was actionable. A large number of mTOR mutations were found in cervix and uterine primaries, Mayor added. These tumors can be targeted with agents that are currently on the market.


Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.

In a comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors, investigators identified mutations in various pathways. Mayor said that there were a significant number of p53 and Rb mutations, which are very common in neuroendocrine tumors from sites other than the gynecologic tract. This was expected.

There were a significant number of actionable mutations in the gynecologic subgroup, which Mayor said was unexpected. These actionable mutations were found in the mTOR, MEK, and homologous recombination repair pathways. About 60% of the patients had a mutation that was actionable. A large number of mTOR mutations were found in cervix and uterine primaries, Mayor added. These tumors can be targeted with agents that are currently on the market.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x